Tandem Diabetes Care, Inc. (TNDM) Stock Forecast
TNDM analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.96 / 5 from 25 analysts
- Price target
- $27.76 average of analyst targets
- Upside to target
- +70.9% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.27
- 52-week range
- $12.82 – $28.26
TNDM analyst ratings
25 analystsNumber of analysts at each rating.
TNDM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TNDM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.24 | −$0.36 | −$0.16 | −$0.31 | +22.5% | 20 |
| Current fiscal year (2026) | −$0.66 | −$0.91 | −$0.45 | −$2.58 | +74.3% | 21 |
| Next fiscal year (2027) | $0.16 | −$0.30 | $0.57 | −$0.66 | +123.9% | 21 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TNDM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $265.8M | $263.0M | $269.7M | +6.7% | 22 |
| Current fiscal year (2026) | $1.07B | $1.06B | $1.08B | +5.7% | 24 |
| Next fiscal year (2027) | $1.20B | $1.17B | $1.28B | +12.3% | 24 |
TNDM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TNDM revenue: reported and forecast
TNDM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.24 | −$0.24 | −$0.24 | −$0.24 | +21.4% | 3 up · 12 down |
| Current fiscal year (2026) | −$0.71 | −$0.68 | −$0.67 | −$0.66 | −$0.66 | −6.8% | 1 up · 1 down |
| Next fiscal year (2027) | $0.07 | $0.18 | $0.17 | $0.16 | $0.16 | +129.1% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TNDM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TNDM beat in 7 of 12.
What analysts expect from TNDM
25 analysts cover Tandem Diabetes Care; their consensus rating is buy (3.96 on a 1–5 scale, where 5 is a strong buy). The average price target is $27.76, 70.9% above the latest close of $16.24. Analysts expect earnings of −$0.66 per share for 2026, +74.3% from a year earlier. For 2027 the average estimate is $0.16 per share on revenue of $1.2 billion. Tandem Diabetes Care beat the EPS estimate in 7 of the last 12 quarters.
Related: TNDM income statement, TNDM key metrics, TNDM chart. See the TNDM stock overview for the latest quote and news.
TNDM forecast FAQ
What is Tandem Diabetes Care's price target?
The average analyst price target for Tandem Diabetes Care is $27.76, 70.9% above the latest close of $16.24.
Is Tandem Diabetes Care a buy, hold or sell?
Of 25 analysts covering Tandem Diabetes Care, 11 rate it a strong buy, 2 a buy, 12 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Tandem Diabetes Care's EPS forecast?
Analysts forecast −$0.66 per share for 2026 (range −$0.91 to −$0.45); for 2027 the estimate is $0.16.
What is Tandem Diabetes Care's revenue forecast?
The average revenue estimate for 2026 is $1.1 billion, growth of 5.7%; for 2027 it is $1.2 billion.
When does Tandem Diabetes Care report earnings?
Tandem Diabetes Care is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.27.
Does Tandem Diabetes Care usually beat earnings estimates?
Tandem Diabetes Care reported EPS at or above the analyst estimate in 7 of the last 12 quarters.